TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8294627
Drug: Control (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Standard medical therapy alone)
Study: 3555040
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg orally every 12 hours for a mean duration of 9.6 days (six to 18 days)
Study: 3555040
Drug: Cefotaxime 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2.0 g intravenously every eight hours for a mean duration of 9.3 days (five to 14 days)
Study: 22302665
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids applied with a squirt system
Study: 22302665
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids applied with a nasal spray
Study: 15742410
Drug: r-hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hepatitis B vaccine (BEVAC)
Study: 12822626
Drug: Sole therapy
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole therapy TMR
Study: 7720988
Drug: 4-ASA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-ASA (2 g)
Study: 7720988
Drug: 5-ASA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA (1 g)
Study: 2041662
Drug: Dexamethasone adjunctive
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone adjunctive treatment
Study: 26403465
Drug: Monthly dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dihydroartemisinin-piperaquine (DHA/PQ)
Study: 26403465
Drug: Monthly dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dihydroartemisinin-piperaquine (DHA/PQ) with low PQ exposure
Study: 26403465
Drug: Monthly dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dihydroartemisinin-piperaquine (DHA/PQ) with medium PQ exposure
Study: 26403465
Drug: Monthly dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly dihydroartemisinin-piperaquine (DHA/PQ) with high PQ exposure
Study: 22087077
Drug: Artemisinin-based combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-based combination therapy (ASAQ)
Study: 17690340
Drug: Mix of
Normalized name: PHLEUM PRATENSE POLLEN 40000 [BAU] in 1 mL / DACTYLIS GLOMERATA POLLEN 20000 [BAU] in 1 mL / POA PRATENSIS POLLEN 20000 [BAU] in 1 mL / AGROSTIS GIGANTEA POLLEN 20000 [BAU] in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [MIDWEST MIX OF STANDARDIZED GRASS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mix of four bacterial strains (L delbrueckii var bulgaricus, Streptococcus thermophilus, L acidophilus, and Bifidobacterium bifidum)
Study: 17690340
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (control group)
Study: 11306905
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (110‐285 IU/kg/day) administered via continuous intravenous infusion after surgery until mobilization the next day
Study: 11306905
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (150‐199 IU/kg/day)
Study: 11306905
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (200‐285 IU/kg/day)
Study: 2371371
Drug: 2,500 lux
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,500 lux treatment for 2 hours (previous studies)
Study: 31670808
Drug: Gentamicin 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 240 mg plus Azithromycin 1 g
Study: 31670808
Drug: Ceftriaxone 500
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 500 mg plus Azithromycin 1 g
Study: 24972643
Drug: Alcohol and
Normalized name: Polyvinyl alcohol and povidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol and drug addictions
Study: 24972643
Drug: Realistic opinion
Normalized name: REALIST ORBCEL-C
DrugBank: Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells (DB15731)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Realistic opinion about the causes and treatment of schizophrenia, anxiety, bulimia, and depression
Study: 23558598
Drug: Hemodynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodynamic treatment based on impedance cardiography
Study: 19845417
Drug: Vigabatrin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin treatment (Group I)
Study: 19845417
Drug: No vigabatrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vigabatrin treatment (Group III)
Study: 19845417
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of vigabatrin therapy
Study: 19845417
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily dose of vigabatrin
Study: 15507097
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with Pangramin SLIT; 0.5 microg major allergens, three times per week for 32 months
Study: 11136681
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of enoxaparin during predilation with reduced systemic heparinization
Study: 11136681
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of enoxaparin
Study: 9232300
Drug: Albuterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (2 puffs)
Study: 8124904
Drug: Daily morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily morning administration of prednisolone
Study: 8124904
Drug: Alternate-day administration
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day administration of prednisolone
Study: 8124904
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment in patients with GCA
Study: 30982843
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTA) - 155 units, 31 injections
Study: 23288418
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (0.7 ml/kg)
Study: 23288418
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (0.5 ml/kg)
Study: 21769850
Drug: Imatinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 200 mg administered twice a day
Study: 12567339
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with epinephrine (5 microg/mL) instilled for 20 seconds
Study: 12567339
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with epinephrine (5 microg/mL) instilled for 60 seconds
Study: 12567339
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.25 mL/kg instilled for 20 or 60 seconds
Study: 1832904
Drug: Intravenous CMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CMF (modified 3-weekly schedule)
Study: 6349648
Drug: Meclofenamate sodium
Normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meclofenamate sodium (200 mg initially, then 100 mg every 4 hours for 24 hours, followed by 100 mg every 8 hours for 6 days)
Study: 6349648
Drug: Indometacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (25 mg initially, then 25 mg every 4 hours for 24 hours, followed by 50 mg every 8 hours for 6 days)
Study: 20964865
Drug: 20 ml/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml/day anti‐inflammatory dose fish oil (3.6 g eicosapentaenoic acid, 2.4 g docosahexanoic acid)
Study: 20964865
Drug: 20 ml/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml/day low dose fish oil (0.36 g eicosapentaenoic acid, 0.24 g docosahexanoic acid)
Study: 15990174
Drug: Hyaluronate receptor
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronate receptor (CD44) expression during relapses
Study: 9450771
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (IFNbeta-1a; AVONEX), 30 microg once weekly by intramuscular injection
Study: 7887548
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy with three or more daily insulin injections or continuous subcutaneous insulin infusion guided by four or more glucose tests per day
Study: 7887548
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with one or two daily insulin injections
Study: 11684933
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rifampicin-containing regimens (3HR and 3HRZ)
Study: 386698
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g/day for 6 weeks
Study: 386698
Drug: Gefarnate 250
Normalized name: gefarnate
DrugBank: Gefarnate (DB12079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefarnate 250 mg/day for 6 weeks
Study: 22573127
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 10 mg (up-titrated to 20 and 40 mg)
Study: 22573127
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg (up-titrated to 5 and 10 mg)
Study: 15867334
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy and diet (n = 5)
Study: 14692469
Drug: melatonin 6
Normalized name: melatonin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin 6 mg
Study: 8821299
Drug: HDM allergen
Normalized name: American house dust mite allergenic extract 6 SQ-HDM / European house dust mite allergenic extract 6 SQ-HDM [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM allergen measurement using monoclonal antibody enzyme linked immunosorbent assay (ELISA)
Study: 2119555
Drug: Intravenous fibronectin
Normalized name: Fibronectin
DrugBank: Fibronectin (DB15150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fibronectin (7.5 mg.kg‐1.d‐1 for 4 days)
Study: 30928884
Drug: MABT (Mindful
Approvals — FDA: no, EMA: no, PMDA: no
Description: MABT (Mindful Awareness in Body‐oriented Therapy)
Study: 27627630
Drug: brief remoralization
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: brief remoralization treatment
Study: 27627630
Drug: brief exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: brief exposure treatment
Study: 15212867
Drug: Care co-ordination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care co-ordination (CC) program involving care planning by a general practitioner (GP) and graduated case management.
Study: 15212867
Drug: Care co-ordination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care co-ordination (CC) program
Study: 11171680
Drug: Continued methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continued methotrexate treatment (group A)
Study: 11171680
Drug: Discontinued methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Discontinued methotrexate treatment (group B)
Study: 11171680
Drug: No methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No methotrexate treatment (group C)
Study: 9764335
Drug: Artesunate with
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate with mefloquine (25 mg/kg)
Study: 8043556
Drug: Prostaglandin synthetase
Normalized name: nitric oxide synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin synthetase inhibitors
Study: 25376453
Drug: Gonadotrophin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin-releasing hormone analogues
Study: 3061354
Drug: Jelonet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jelonet and Whitehead's varnish (compound iodoform paint BPC)
Study: 29267519
Drug: 400mg Ibuprofen
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg Ibuprofen 60 min preemptive + 400mg Ibuprofen postoperative
Study: 26645254
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN, 5 mg/d for 7 days)
Study: 26645254
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN) in patients randomized within 6 hours
Study: 25268838
Drug: n‐3 FA‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 FA‐enriched oral nutritional supplement (ONS) providing 2.0 g of eicosapentaenoic acid (EPA) and 1.0 g of docosahexaenoic acid (DHA) per day
Study: 18972730
Drug: Small needle-knife
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small needle-knife comprehensive therapy
Study: 17010793
Drug: Consistent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consistent therapy with enoxaparin
Study: 1302750
Drug: Stimuliv (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimuliv (2 tablets thrice daily)
Study: 3924553
Drug: acarbose (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: acarbose (3 X 100 mg/day)
Study: 31262265
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca block using 30 ml of bupivacaine 0.5% with epinephrine 1:200,000
Study: 31262265
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection with normal saline
Study: 26829251
Drug: Nifedipine GITS/Candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine GITS/Candesartan combination therapy (N: 20, 30, or 60 mg; C: 4, 8, 16, or 32 mg daily)
Study: 26829251
Drug: Nifedipine GITS/Candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine GITS/Candesartan combination therapy
Study: 22699818
Drug: L-thyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (L-T4) treatment for 24 months
Study: 11856082
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ridogrel once daily
Study: 11856082
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ridogrel once daily
Study: 11856082
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg ridogrel once daily
Study: 11856082
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ridogrel once daily (International trial)
Study: 11856082
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ridogrel once daily (International trial)
Study: 11856082
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg ridogrel once daily (International trial)
Study: 11856082
Drug: Mesalazine 800
Normalized name: mesalazine 800 MG Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine 800 mg three times daily (International trial)
Study: 8617528
Drug: Furazolidone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone (7.5 mg/kg/day)
Study: 8617528
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid (55 mg/kg/day)
Study: 16645545
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogens (CEE) and 2.5 mg of medroxyprogesterone acetate (MPA) daily
Study: 16645545
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated equine estrogens (CEE) and 2.5 mg of medroxyprogesterone acetate (MPA) on alternate days
Study: 10958375
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (glucose only, MG)
Study: 1993037
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin therapy (325 mg on alternate days)
Study: 1993037
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin therapy (325 mg on alternate days) among younger men (aged 40 to 59 years)
Study: 6224001
Drug: 0.1% octenidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% octenidine in aqueous solution
Study: 31353819
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (NSPT) with preparatory 15-day decontamination phase including chlorhexidine mouth rinse and domiciliary hygiene instructions (modified FMD: test group)
Study: 31353819
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (NSPT) without preparatory decontamination (FMD: control group)
Study: 31353819
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (NSPT) with modified FMD (test group)
Study: 28632508
Drug: Dextroamphetamine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine with transcranial direct current stimulation and speech and language therapy
Study: 28632508
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with transcranial direct current stimulation and speech and language therapy
Study: 25109699
Drug: PEG‐IFN treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN treatment for 1 year
Study: 25109699
Drug: HLA‐DPB1 G-allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA‐DPB1 G-allele
Study: 16803911
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 1 mug.kg(‐1) iv during induction, continuous infusion at 0.5 mug.kg(‐1).hr(‐1))
Study: 16803911
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline, volume-matched bolus and infusion)
Study: 8807071
Drug: Rifabutin 600
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 600 mg/day
Study: 6377466
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg cimetidine daily
Study: 6377466
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg trimipramine daily
Study: 30160183
Drug: Shortened contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shortened contrast injection (8 seconds) in group A
Study: 30160183
Drug: Standard contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard contrast injection (10 seconds) in group B
Study: 19394469
Drug: Ice cream
Normalized name: Nice Cream 2% Topical Dental Foam (mint)
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice cream (3% butterfat)
Study: 19394469
Drug: Ice cream
Normalized name: Nice Cream 2% Topical Dental Foam (mint)
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice cream (9% coconut oil)
Study: 12926838
Drug: 0.6 million
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 million international units (MIU) of oral interferon beta-1a
Study: 12926838
Drug: 0.06 million
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 million international units (MIU) of oral interferon beta-1a
Study: 12926838
Drug: 6 million
Normalized name: INTERFERON ALFA-2A,RECOMBINANT 6 MILLION UNT/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 million international units (MIU) of oral interferon beta-1a
Study: 11005498
Drug: Rectal mobilization
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal mobilization
Study: 1457264
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (4 x 100 micrograms)
Study: 6363157
Drug: Acidrine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidrine (2 tablets t.i.d. for 8 weeks)
Study: 6363157
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets t.i.d. for 8 weeks)
Study: 26324322
Drug: Movement System
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement System Impairment (MSI) treatment
Study: 22367794
Drug: Immunonutrition (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrition (1000 ml/day for 5 days before surgery)
Study: 18558642
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus day hospital treatment
Study: 18558642
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus day hospital treatment
Study: 12480497
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IL-2 at doses of 10,000 IU/kg bw
Study: 12480497
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IL-2 at doses of 1000 IU/kg bw
Study: 10361648
Drug: Standard discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard discharge preparation (control)